Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What is the therapeutic index of the drug based on the provided dose-response curve (DRC)?

21. ***21*** - The **therapeutic index (TI)** is calculated as **TD50/ED50**, where TD50 is the dose causing toxicity in 50% of subjects and ED50 is the dose producing therapeutic effect in 50% of subjects. - A TI of 21 indicates a **relatively safe drug** with a good margin between therapeutic and toxic doses, allowing for safer clinical use. *8* - This value represents a **narrow therapeutic window**, suggesting the drug would be too close to toxic levels for safe clinical use. - A TI of 8 would indicate **higher risk of toxicity** at therapeutic doses, making it less desirable than the calculated value of 21. *128* - This value is **too high** based on the dose-response curve data, likely representing an overestimation of the safety margin. - A TI of 128 would suggest an **extremely wide therapeutic window**, which doesn't match the typical pharmacokinetic profile shown in the curve. *1024* - This represents an **unrealistically high therapeutic index** that would indicate virtually no risk of toxicity at therapeutic doses. - Such a high TI value is **inconsistent** with the dose-response relationship demonstrated in the provided curve data.

Q: What type of antagonism is observed between acetylcholine and atropine?

Competitive antagonism. **Explanation:** **1. Why Competitive Antagonism is Correct:** Acetylcholine (ACh) and Atropine compete for the same binding site on the **muscarinic receptors**. In competitive (reversible) antagonism, the antagonist binds to the receptor site, preventing the agonist from binding. This inhibition can be overcome by increasing the concentration of the agonist (ACh), which shifts the dose-response curve to the **right** without changing the maximal response ($E_{max}$). **2. Why Other Options are Incorrect:** * **Physiological Antagonism:** This occurs when two drugs act on **different receptors** to produce opposite physiological effects (e.g., Histamine causing bronchoconstriction via $H_1$ receptors vs. Adrenaline causing bronchodilation via $\beta_2$ receptors). ACh and Atropine act on the *same* receptor. * **Noncompetitive Antagonism:** Here, the antagonist binds to an allosteric site or binds irreversibly to the active site. Increasing the agonist concentration cannot overcome this block, leading to a decrease in the maximal response ($E_{max}$). **3. NEET-PG High-Yield Pearls:** * **Surmountable Blockade:** Competitive antagonism is "surmountable." * **Graph Shift:** Look for a **parallel shift to the right** in the Log Dose-Response (LDR) curve. * **Dissociation Constant ($K_d$):** In competitive antagonism, the $K_d$ (or $EC_{50}$) increases, but the efficacy remains unchanged. * **Clinical Example:** Atropine is the drug of choice for **Organophosphate poisoning** to competitively block the excess ACh at muscarinic sites.

Q: All of the following agents act through nuclear receptors EXCEPT?

Prednisolone. **Explanation:** The question asks for the agent that does **not** act through a nuclear receptor. While all options listed are lipid-soluble hormones or drugs that act on intracellular receptors, there is a specific distinction in their localization. **1. Why Prednisolone is the correct answer:** Glucocorticoids like **Prednisolone** act on the **Glucocorticoid Receptor (GR)**, which is a **Cytoplasmic receptor** (Type I Nuclear Receptor subfamily) [2]. In its inactive state, the GR is bound to Heat Shock Proteins (HSP-90) in the cytoplasm [3]. Upon ligand binding, the receptor dissociates from HSPs, dimerizes, and translocates into the nucleus to modulate gene transcription [2]. Therefore, strictly speaking, its primary location is the cytoplasm, not the nucleus. **2. Why the other options are incorrect:** * **Thyroxine (T4):** Acts on Thyroid Hormone Receptors (TR) which are **constitutively located in the nucleus**, bound to DNA even in the absence of a ligand [4]. * **Rosiglitazone:** This is a Thiazolidinedione (TZD) that acts on **PPAR-gamma** (Peroxisome Proliferator-Activated Receptor gamma), which is a **nuclear receptor** [1]. * **Estrogen:** Acts on Estrogen Receptors (ER). Unlike glucocorticoid receptors, ERs are primarily **located in the nucleus** (Type II) even before the hormone binds. **High-Yield Clinical Pearls for NEET-PG:** * **Cytoplasmic Receptors:** Remember the mnemonic **"VAG"** — **V**itamin D (can be both, but often grouped here), **A**ldosterone (Mineralocorticoids), and **G**lucocorticoids. * **Nuclear Receptors:** Remember **"RET"** — **R**etinoic acid, **E**strogen/Progesterone, and **T**hyroid hormone (T3/T4). * **Mechanism:** All these receptors act as **ligand-activated transcription factors**, leading to a lag period in action (hours to days) and a persistent effect even after the drug is cleared.

Q: What is the value of intrinsic activity for a partial agonist?

Between 0 and +1. ### Explanation **Intrinsic Activity (α)** refers to the ability of a drug to activate a receptor and produce a maximal biological response once it has bound to it. It is measured on a scale from -1 to +1. **Why the Correct Answer is Right:** A **Partial Agonist** binds to a receptor but, even at 100% receptor occupancy, it cannot elicit the maximal response (Emax) that a full agonist would. Therefore, its intrinsic activity is greater than zero (it does produce a response) but less than one (the response is sub-maximal). * **Mathematical Value:** 0 < α < 1. * **Clinical Significance:** In the presence of a full agonist, a partial agonist acts as a **competitive antagonist** because it occupies receptors but produces a weaker effect, effectively "damping" the overall response (e.g., Buprenorphine in opioid use). **Why Other Options are Wrong:** * **Option A (1):** This is the intrinsic activity of a **Full Agonist**, which produces the maximum possible biological response. * **Option B (0):** This is the intrinsic activity of a **Competitive Antagonist**. It has affinity (binds to the receptor) but zero intrinsic activity (produces no response). * **Option D (-1):** This is the intrinsic activity of an **Inverse Agonist**. It binds to the receptor and produces an effect opposite to that of an agonist (decreases constitutive activity). **High-Yield NEET-PG Pearls:** 1. **Affinity vs. Intrinsic Activity:** All agonists and antagonists have affinity, but only agonists (full/partial/inverse) have intrinsic activity. 2. **Pindolol:** A classic example of a partial agonist (Beta-blocker with Intrinsic Sympathomimetic Activity). 3. **Varenicline:** A partial agonist at nicotinic receptors used for smoking cessation. 4. **Aripiprazole:** An atypical antipsychotic that acts as a partial agonist at $D_2$ receptors.

Q: Which of the following H1 receptor antagonists does not have an active metabolite?

Mizolastine. ### Explanation The correct answer is **Mizolastine**. **1. Why Mizolastine is the correct answer:** Mizolastine is a second-generation H1 receptor antagonist [2] characterized by its unique metabolic profile. Unlike many other antihistamines in its class [1], Mizolastine is primarily metabolized in the liver via **glucuronidation** and oxidation into **inactive metabolites**. It does not rely on the formation of an active metabolite to exert its therapeutic effect, which contributes to its predictable pharmacokinetics and lower potential for drug-drug interactions compared to those requiring CYP450 activation. **2. Why the other options are incorrect:** * **Loratadine:** It is a prodrug that is extensively metabolized by CYP3A4 and CYP2D6 into its potent active metabolite, **Desloratadine** [1, 2]. * **Azelastine:** This phthalazinone derivative [2] is metabolized into an active metabolite, **Desmethylazelastine**, which contributes to its long duration of action. * **Ebastine:** It is a prodrug that undergoes near-complete first-pass metabolism by CYP3A4 to form its active metabolite, **Carebastine**. **3. NEET-PG High-Yield Clinical Pearls:** * **Active Metabolite Pairs:** Remember the pairs for exams: Terfenadine → Fexofenadine; Loratadine → Desloratadine; Ebastine → Carebastine; Hydroxyzine → Cetirizine [1, 2]. * **Mizolastine Unique Features:** It has a dual mechanism —it blocks H1 receptors and also inhibits the release of inflammatory mediators (like leukotrienes) from mast cells. * **Safety Note:** Unlike its predecessors (Terfenadine and Astemizole), Mizolastine has a significantly lower risk of causing Torsades de Pointes (QT prolongation), though caution is still advised with potent CYP3A4 inhibitors.

Q: Which of the following drugs does NOT exhibit first-pass metabolism?

Salicylates. ### Explanation **Concept: First-Pass Metabolism** First-pass metabolism (presystemic elimination) is the phenomenon where a drug is metabolized in the gut wall or liver before reaching the systemic circulation. This significantly reduces the bioavailability of orally administered drugs. **Why Salicylates is the Correct Answer:** Salicylates (such as Aspirin) are rapidly absorbed from the stomach and upper small intestine. While they undergo metabolism in the liver, they do **not** undergo significant first-pass metabolism that limits their systemic availability. They have high oral bioavailability (approx. 70–100%). In contrast, the other options are classic examples of drugs with high first-pass extraction. **Analysis of Incorrect Options:** * **Nitroglycerine (B):** This drug has the highest first-pass metabolism (nearly 100%). This is why it is administered sublingually to bypass the liver and reach the coronary arteries immediately. * **Morphine (A):** Morphine undergoes extensive glucuronidation in the liver. Its oral dose is significantly higher than its parenteral dose due to this high first-pass effect. * **Propranolol (C):** A classic example of a drug with high hepatic extraction. Only about 25% of an oral dose reaches the systemic circulation. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for High First-Pass Metabolism:** "**L**ive **N**ightly **P**roperly **M**eta **I**s **S**o **H**ard" (**L**ignocaine, **N**itroglycerine, **P**ropranolol, **M**orphine, **I**mipramine, **S**albutamol, **H**ydrocortisone). * **Routes to bypass first-pass:** Sublingual, Transdermal, and Rectal (partial bypass—lower 1/3rd of the rectum). * **Bioavailability ($F$):** For IV administration, $F = 100\%$. For drugs with high first-pass metabolism, $F$ is significantly low.

Q: Which drug is administered as a racemic mixture of two enantiomers with different pharmacokinetic and pharmacodynamic properties?

Verapamil. **Explanation:** **Verapamil** is a classic example of a drug administered as a **racemic mixture** where the two enantiomers exhibit distinct properties. * **Pharmacodynamics:** The **L-isomer (S-verapamil)** is significantly more potent (10–20 times) as a calcium channel blocker compared to the D-isomer (R-verapamil). * **Pharmacokinetics:** Verapamil undergoes stereoselective first-pass metabolism. The L-isomer is metabolized more rapidly than the D-isomer. This explains why oral doses of verapamil must be much higher than intravenous doses to achieve the same therapeutic effect, as the more active L-isomer is heavily cleared by the liver before reaching systemic circulation. **Analysis of Incorrect Options:** * **A. Dilantin (Phenytoin):** This is an achiral molecule (it does not have a chiral center) and therefore does not exist as enantiomers. It is known for its zero-order kinetics at high therapeutic doses. * **B. Digoxin:** This is a complex steroid glycoside derived from the foxglove plant. While it has multiple chiral centers, it is purified as a single natural stereoisomer, not a racemic mixture. * **D. Octreotide:** This is a synthetic cyclic octapeptide (somatostatin analogue). It consists of specific L- and D-amino acids in a fixed sequence, but it is not administered as a racemic mixture of two mirror-image molecules. **NEET-PG High-Yield Pearls:** * **Other Racemic Mixtures:** Warfarin, Ketamine, and Ibuprofen. * **Single Enantiomers:** Some drugs are developed as single isomers to reduce side effects (e.g., **Levocetirizine** from Cetirizine, **Esomeprazole** from Omeprazole, and **S-Amlodipine**). * **Clinical Note:** The stereoselective metabolism of Verapamil is a frequent exam topic regarding the "First Pass Effect."

Question 1

What is the therapeutic index of the drug based on the provided dose-response curve (DRC)?

Accepted Answer

21

Answer

8

Answer

128

Answer

1024

Question 2

The pharmacokinetics of Paroxetine include its ability to be easily absorbed after oral administration in healthy volunteers even after food is ingested. Which of the following is TRUE regarding Paroxetine's pharmacokinetics?

Accepted Answer

Less than 1% of the drug is in systemic circulation owing to extensive distribution in body tissues.

Answer

The main portion of the medication resides in systemic circulation.

Answer

Little of the medication is absorbed into the tissues.

Answer

Less than 25% is eliminated by the kidneys.

Question 3

Which of the following most accurately describes the transmembrane signaling process involved in the steroid hormone action?

Accepted Answer

Diffusion across the membrane and binding to an intracellular receptor

Answer

Action on a membrane spanning tyrosine kinase

Answer

Action of a G protein, which activates or inhibits adenylyl cyclase

Answer

Opening of transmembrane ion channels

Question 4

All of the following statements regarding volume of distribution are true except?

Accepted Answer

It is calculated by multiplying the half-life by log base 2.

Answer

Half-life is usually proportional to Vd.

Answer

Skeletal muscle relaxants generally have a low volume of distribution.

Answer

Drugs with high plasma protein binding tend to have a low volume of distribution.

Question 5

What type of antagonism is observed between acetylcholine and atropine?

Accepted Answer

Competitive antagonism

Answer

Physiological antagonism

Answer

Noncompetitive antagonism

Answer

None of the above

Question 6

All of the following agents act through nuclear receptors EXCEPT?

Accepted Answer

Prednisolone

Answer

Thyroxine

Answer

Rosiglitazone

Answer

Estrogen

Question 7

What is the value of intrinsic activity for a partial agonist?

Accepted Answer

Between 0 and +1

Answer

1

Answer

0

Answer

-1

Question 8

Which of the following H1 receptor antagonists does not have an active metabolite?

Accepted Answer

Mizolastine

Answer

Loratidine

Answer

Azelastine

Answer

Ebastine

Question 9

Which of the following drugs does NOT exhibit first-pass metabolism?

Accepted Answer

Salicylates

Answer

Morphine

Answer

Nitroglycerine

Answer

Propranolol

Question 10

Which drug is administered as a racemic mixture of two enantiomers with different pharmacokinetic and pharmacodynamic properties?

Accepted Answer

Verapamil

Answer

Dilantin

Answer

Digoxin

Answer

Octreotide

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?